Healthcare provider profile · identity verified

Eric Faught, CRNP

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PUNXSUTAWNEY, PA · NPI 1043927775

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Eric Faught, CRNP received $22.70 in general payments during 2025 across 1 reported records.

Smith+Nephew, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$22.70

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Smith+Nephew, Inc. Unresolved — no canonical attribution shown $22.70100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$22.701

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
PICO
Normalized: pico
Device Smith+Nephew, Inc. $22.70 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
LisinoprilLisinopril27491
Atorvastatin CalciumAtorvastatin Calcium25078
Pantoprazole SodiumPantoprazole Sodium18758
GabapentinGabapentin17260
OmeprazoleOmeprazole14942
Levothyroxine SodiumLevothyroxine Sodium13339
Metformin HclMetformin Hcl11040
Amlodipine BesylateAmlodipine Besylate10938
FurosemideFurosemide10230
Potassium ChloridePotassium Chloride9121
Metoprolol TartrateMetoprolol Tartrate8122
HydrochlorothiazideHydrochlorothiazide7927
Albuterol Sulfate HfaAlbuterol Sulfate7624
JardianceEmpagliflozin6920
Escitalopram OxalateEscitalopram Oxalate6415
Losartan PotassiumLosartan Potassium6319
AtenololAtenolol6116
BaclofenBaclofen6123
SimvastatinSimvastatin5720
Rosuvastatin CalciumRosuvastatin Calcium5321
Fluticasone PropionateFluticasone Propionate5123
TrulicityDulaglutide5113
ClopidogrelClopidogrel Bisulfate5015
Cyclobenzaprine HclCyclobenzaprine Hcl4820
EliquisApixaban47suppressed
Tamsulosin HclTamsulosin Hcl4715
Metoprolol SuccinateMetoprolol Succinate4415
OzempicSemaglutide42suppressed
Trazodone HclTrazodone Hcl4012
Lantus SolostarInsulin Glargine,hum.Rec.Anlog3812
CarvedilolCarvedilol3613
Duloxetine HclDuloxetine Hcl3613
FamotidineFamotidine3412
Montelukast SodiumMontelukast Sodium32suppressed
Metformin Hcl ErMetformin Hcl29suppressed
Bupropion XlBupropion Hcl28suppressed
NaproxenNaproxen28suppressed
Sertraline HclSertraline Hcl2813
LevetiracetamLevetiracetam27suppressed
Ondansetron HclOndansetron Hcl27suppressed
Diclofenac SodiumDiclofenac Sodium25suppressed
ValsartanValsartan25suppressed
AllopurinolAllopurinol24suppressed
Pravastatin SodiumPravastatin Sodium24suppressed
Zolpidem TartrateZolpidem Tartrate24suppressed
IbuprofenIbuprofen2312
EzetimibeEzetimibe22suppressed
MeloxicamMeloxicam22suppressed
XareltoRivaroxaban21suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20suppressed
GlipizideGlipizide20suppressed
MirtazapineMirtazapine20suppressed
Quetiapine FumarateQuetiapine Fumarate20suppressed
LorazepamLorazepam19suppressed
Meclizine HclMeclizine Hcl19suppressed
Oxybutynin ChlorideOxybutynin Chloride19suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl18suppressed
FenofibrateFenofibrate Nanocrystallized18suppressed
PregabalinPregabalin18suppressed
Citalopram HbrCitalopram Hydrobromide17suppressed
Sumatriptan SuccinateSumatriptan Succinate17suppressed
TradjentaLinagliptin17suppressed
SpironolactoneSpironolactone16suppressed
SynthroidLevothyroxine Sodium16suppressed
Ventolin HfaAlbuterol Sulfate16suppressed
Breo ElliptaFluticasone/Vilanterol15suppressed
Dicyclomine HclDicyclomine Hcl15suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide15suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15suppressed
Ropinirole HclRopinirole Hcl15suppressed
AmoxicillinAmoxicillin1414
Betamethasone DipropionateBetamethasone Dipropionate14suppressed
ClonazepamClonazepam14suppressed
MethylprednisoloneMethylprednisolone1413
Ondansetron OdtOndansetron14suppressed
Amiodarone HclAmiodarone Hcl13suppressed
Doxycycline HyclateDoxycycline Hyclate1311
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide13suppressed
MovantikNaloxegol Oxalate13suppressed
Propranolol HclPropranolol Hcl13suppressed
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril12suppressed
AzithromycinAzithromycin1212
Droplet Pen NeedlePen Needle, Diabetic12suppressed
RoflumilastRoflumilast12suppressed
Tramadol HclTramadol Hcl12suppressed
AlprazolamAlprazolam11suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $22.70 · 1 records Smith+Nephew, Inc. PICO
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error